This report is designed for companies and decision-makers seeking actionable insights on market size, growth, trends, and competitive strategies to drive expansion and success in the Cimzia industry.
What is the projected value of the cimzia market by 2029?
The cimzia market size has grown rapidly in recent years. It will grow from $3,030.21 million in 2024 to $3,567.52 million in 2025 at a compound annual growth rate (CAGR) of 17.7%. The growth in the historic period can be attributed to an increase in the prevalence of autoimmune diseases, a growth in awareness of biological therapies, a rise in healthcare expenditure, increased adoption of self-injectable biologics, and a growth in biologic drug manufacturing capacity.
The cimzia market size is expected to see rapid growth in the next few years. It will grow to $6,776.61 million in 2029 at a compound annual growth rate (CAGR) of 17.4%. The growth in the forecast period can be attributed to rising demand for targeted biologics, increasing patient preference for self-administration devices, growth in biosimilar competition, increasing government healthcare funding, and growing emphasis on personalized medicine. Major trends in the forecast period include shift towards patient-centric drug delivery solutions, adoption of digital health tools for disease management, increasing use of real-world evidence in drug development, growth of telemedicine and home care solutions, and integration of AI in clinical trials.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19889&type=smp
How are technological advancements fueling growth in the cimzia market?
The rise in the prevalence of rheumatoid arthritis is expected to propel the growth of the cimzia market going forward. Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by the immune system mistakenly attacking the body’s own joint tissues, leading to inflammation, pain, and swelling in the joints. The rise in the prevalence of rheumatoid arthritis (RA) can be attributed to an aging population, increasing genetic predisposition, environmental triggers like smoking and pollution, and heightened awareness and improved diagnosis of the disease. Cimzia contributes significantly to addressing the growing prevalence of rheumatoid arthritis by delivering targeted therapy that minimizes inflammation, eases symptoms, enhances patient well-being, and supports better disease management. For instance, in May 2022, according to the Pain Relief Foundation, a UK-based charity, arthritis and musculoskeletal conditions impact over 17 million people in the UK, causing 30 million lost working days annually, while chronic pain affects up to 62% of those over 75. Additionally, in February 2024, according to the data published by the Centers for Disease Control and Prevention, a US-based national public health agency, the age-adjusted prevalence of diagnosed arthritis in adults aged 18 and older was 18.9% in 2022, with women (21.5%) being more likely to have arthritis than men (16.1%). Therefore, the increase in prevalence of rheumatoid arthritis is driving the growth of the cimzia market.
Which segment currently leads the cimzia market in terms of revenue share?
The cimzia market covered in this report is segmented –
1) By Type: Biologics; Biosimilars
2) By Patient Demographics: Adults; Pediatrics
3) By Distribution Channels: Hospital Pharmacies; Drug Stores And Retail Pharmacies; Online Pharmacies
4) By Application: Crohn’s Disease; Rheumatoid Arthritis; Ankylosing Spondylitis; Active Psoriatic Arthritis; Axial Spondyloarthritis; Plaque Psoriasis
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/cimzia-global-market-report
What technological trends are expected to redefine the cimzia market?
The key trend in the Cimzia market is focusing on developing innovative treatments, such as autoimmune therapy solutions, to expand treatment options for patients with non-radiographic axial spondyloarthritis, addressing an unmet medical need in autoimmune disease management. Autoimmune therapy solutions are treatments designed to manage autoimmune diseases by restoring immune balance and tolerance, often using targeted immunotherapies and cellular therapies. For instance, in July 2024, UCB, a Belgium-based biopharmaceutical company, announced the expansion of CIMZIA (certolizumab pegol) as a treatment option for patients with non-radiographic axial spondyloarthritis (nr-axSpA). This expansion aims to provide an innovative therapy option for those who have not yet developed radiographic evidence of the disease but continue to experience symptoms. CIMZIA is the first and only biologic with FDA approval for nr-axSpA, highlighting its unique position in the autoimmune treatment landscape. The approval offers a crucial alternative to traditional therapies, helping patients who suffer from this inflammatory condition gain improved symptom management and quality of life.
Who are the top competitors in the global cimzia market?
Major companies operating in the cimzia market include UCB SA
What regional dynamics are shaping the future of the global cimzia market?
North America was the largest region in the cimzia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cimzia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Cimzia Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19889
Need Customized Data On Cimzia Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=19889&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
